Viral Protein Patents (Class 536/23.72)
  • Publication number: 20140154283
    Abstract: Described herein is the identification and of a potent West Nile virus (WNV) CD4 positive T cell epitope and its use for increasing the immunogenicity of heterologous flavivirus vaccines, such as dengue virus type 2 (DENV-2) DNA and virus-like particle (VLP) vaccines. Also described are methods for the identification of potent T cell epitopes to enhance immunogenicity of multivalent vaccines.
    Type: Application
    Filed: July 11, 2012
    Publication date: June 5, 2014
    Applicants: Department of health and Human Services
    Inventors: Gwong-Jen J. Chang, Holly R. Hughes
  • Publication number: 20140155476
    Abstract: A recombinant vector comprises simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -38 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -383 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 5, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Soumitra Roy, James M. Wilson, Luk H. Vandenberghe
  • Patent number: 8741309
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: June 3, 2014
    Assignees: The United States of America as represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Publication number: 20140147458
    Abstract: The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient.
    Type: Application
    Filed: February 24, 2012
    Publication date: May 29, 2014
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Geun Hee Kim, Shi Nae Kwon, Chan Hee Lee, Yeop Yoon
  • Publication number: 20140147460
    Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 29, 2014
    Applicants: XIAMEN INNOVAX BIOTECH CO. LTD., XIAMEN UNIVERSITY
    Inventors: Shaowei Li, Xianglin Kong, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
  • Publication number: 20140148586
    Abstract: Described herein is a soluble HIV-1 retrovirus transmembrane glycoprotein gp41 trimer (Soc-gp41M-Fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (Soc) protein of bacteriophage T4 and the Foldon domain of the bacteriophage T4 fibritin (Fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of HIV-1 vaccines, diagnostics and therapeutics. Other secondary embodiments of the gp41 proteins containing different modifications are also disclosed. According to one embodiment, the gp41 trimer is further attached to a cell penetration peptide (CPP). Methods of producing gp41 trimers are also disclosed.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 29, 2014
    Applicant: THE CATHOLIC UNIVERSITY OF AMERICA
    Inventors: Venigalla B. RAO, Guofen GAO
  • Publication number: 20140147459
    Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2012. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 29, 2014
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Donald M. Carter, JR.
  • Patent number: 8735561
    Abstract: Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: May 27, 2014
    Assignee: Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences
    Inventors: Xuemei Xu, Ting Zhang, Yufei Xu, Dongsheng Fan
  • Patent number: 8734808
    Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: May 27, 2014
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Sanjay Kapil
  • Patent number: 8729231
    Abstract: The disclosure relates, in some embodiments, to sequences of a novel mutant or variant of the hepatitis B surface antigen (HBsAg) and methods for detecting this genome and protein variant, and antibodies directed against it, from patients' samples.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: May 20, 2014
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Delia Bussfeld, Anne-Sophie Endres, Helga Meisel, Michael Weik
  • Patent number: 8728487
    Abstract: The present disclosure provides an attenuated live vaccine strain and the formulations thereof, for preventing pigs from infection of porcine reproductive and respiratory syndrome (PRRS). The preparation methods for the vaccines and the formulations are also provided. The attenuated live vaccine strain provided herein offers significant immunological protection to pigs against PRRS. The vaccine formulations of the present disclosure also have advantages in long shelf lives as well as good stability during storage.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: May 20, 2014
    Inventors: Hua Wu, Xue Leng, Zhenguang Li, Fengxue Wang
  • Patent number: 8728484
    Abstract: The present invention includes polypeptides, polynucleotides, antibodies, and vaccines associated with Runting Stunting Syndrome (RSS) in poultry. The present invention also includes diagnostic methods based on such polypeptides, polynucleotides, and antibodies and methods of protecting poultry, including chickens, against RSS by the administration of such polypeptides, polynucleotides, antibodies, and vaccines.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: May 20, 2014
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Egbert Mundt, Holly S. Sellers, Guillermo Zavala
  • Publication number: 20140134209
    Abstract: The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 15, 2014
    Applicant: London School of Hygiene & Tropical Medicine
    Inventors: Polly Roy, Mark Boyce
  • Publication number: 20140135384
    Abstract: HERV-K human endogenous retroviruses show up-regulated expression in tumors. In particular, splicing events in the env region generate a series of transcripts which utilize the +2 reading frame, relative to the env reading frame. The proteins show activity typical of transcriptional regulators, and they also have oncogenic potential. Two related proteins, PCAP2 and PCAP3, are strongly associated with breast cancer and prostate cancer, respectively. PCAP4 stimulates cell division. These proteins can be used in cancer diagnosis and therapy, and are also drug targets e.g. for adjuvant therapy. The identification of these splice products is remarkable because full sequence information has been available for HERV-K viruses since 1986.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 15, 2014
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Pablo GARCIA, Stephen F. HARDY, Lewis T. WILLIAMS, Jaime ESCOBEDO
  • Publication number: 20140134604
    Abstract: Replicons of genotype 6 hepatitis C virus (HCV) are provided. These replicons contain adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 6 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 15, 2014
    Inventors: Guofeng Cheng, William E. Delaney, IV, Betty Peng, Mei Yu
  • Publication number: 20140134204
    Abstract: The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing antibody response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine.
    Type: Application
    Filed: April 4, 2012
    Publication date: May 15, 2014
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Gail Bishop, Tony Vanden Bush
  • Publication number: 20140128447
    Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Non-Primate Hepacivirus in an animal. In another aspect, the invention relates to antibodies that bind Non-Primate Hepacivirus polypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing NPHV infection in an animal.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 8, 2014
    Applicant: The Trustees Of Columbia University In The City Of New York
    Inventors: Amit KAPOOR, W. Ian LIPKIN
  • Publication number: 20140127261
    Abstract: Mutations in the central monomer contact interface of the flavivirus envelope protein which modulate the infectivity of the flavivirus are made. The mutations decrease the ability of the envelope dimer protein to dissociate.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 8, 2014
    Applicant: Southern Research Institute
    Inventor: Vladimir Yamshchikov
  • Publication number: 20140127248
    Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: June 20, 2012
    Publication date: May 8, 2014
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles, Corey J. Crevar
  • Publication number: 20140127264
    Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.
    Type: Application
    Filed: March 1, 2012
    Publication date: May 8, 2014
    Inventors: Hèélne Verheije, Carla Christina Schrier
  • Patent number: 8715692
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: May 6, 2014
    Assignee: Novavax, Inc.
    Inventors: Peter Pushko, Yingyun Wu, Michael Massare, Ye Liu, Gale Smith, Bin Zhou
  • Patent number: 8716461
    Abstract: The present invention relates to the discovery of a new human parvovirus, methods of detecting the parvovirus and diagnosing parvovirus infection, methods of treating or preventing parvovirus infection, and methods for identifying anti-parvoviral compounds.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: May 6, 2014
    Assignee: Blood Systems, Inc.
    Inventors: Eric L. Delwart, Morris S. Jones
  • Patent number: 8715691
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: May 6, 2014
    Assignee: MedImmune, LLC
    Inventor: Hong Jin
  • Publication number: 20140120126
    Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 1, 2014
    Applicants: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
  • Publication number: 20140120133
    Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.
    Type: Application
    Filed: October 22, 2013
    Publication date: May 1, 2014
    Applicants: MERIAL LIMITED, UNIVERSITY OF PRETORIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jules Maarten Minke, Jean Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
  • Patent number: 8710207
    Abstract: The present disclosure relates, in some embodiments, to compositions, organisms, systems, and methods for expressing a gene product in a plant using a expression control sequence (ECS) operable in monocots and/or dicots. For example, (i) an isolated nucleic acid may comprise an ECS (e.g., a sugarcane bacilliform virus promoter) and, optionally, an exogenous nucleic acid (ExNA) operably linked to the ECS; (ii) an expression vector may comprise an ECS; an ExNA; and, optionally, a 3? termination sequence, wherein the ECS has promoter activity sufficient to express the ExNA in at least one monocot and at least one dicot; (iii) a microorganism, plant cell, or plant may comprise an isolated nucleic acid; (iv) a method for constitutively expressing an ExNA in a plant (e.g.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: April 29, 2014
    Assignee: The Texas A&M University Systems
    Inventors: T. Erik Mirkov, Jong Won Park, San-Ji Gao
  • Publication number: 20140112923
    Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.
    Type: Application
    Filed: July 25, 2011
    Publication date: April 24, 2014
    Applicant: GREEN CROSS CORPORATION
    Inventors: Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
  • Publication number: 20140105931
    Abstract: This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response.
    Type: Application
    Filed: May 18, 2012
    Publication date: April 17, 2014
    Applicant: EMORY UNIVERSITY
    Inventor: Arash Grakoui
  • Publication number: 20140106982
    Abstract: The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 or PP7 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on bacteriophage VLPs, especially MS2 or PP7 VLPs over a wide range, from few than one—on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 17, 2014
    Inventors: David S. Peabody, Bryce Chackerian
  • Publication number: 20140107014
    Abstract: The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.
    Type: Application
    Filed: October 29, 2013
    Publication date: April 17, 2014
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Andre Lieber, Hongjie Wang
  • Publication number: 20140106340
    Abstract: Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring.
    Type: Application
    Filed: July 5, 2012
    Publication date: April 17, 2014
    Applicants: Health and Human Services
    Inventors: Chunfu Yang, Zhiyong Zhou, Nicholas Wagar, Joshua R. DeVos
  • Patent number: 8697417
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: April 15, 2014
    Assignee: Uniqure IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
  • Publication number: 20140099299
    Abstract: The present invention provides methods and compositions for treating and/or preventing a cytomegalovirus infection in a subject, comprising administering to the subject an effective amount of a cytomegalovirus IL-10 protein modified to have reduced functional activity while retaining immunogenicity. The present invention further provides nucleic acid molecules encoding a cytomegalovirus IL-10 protein or fragment thereof of this invention as well as vectors comprising such nucleic acids. Also provided herein are neutralizing antibodies that specifically bind cmvIL-10.
    Type: Application
    Filed: March 27, 2012
    Publication date: April 10, 2014
    Applicant: UAB Research Foundation
    Inventors: Mark R. Walter, Peter A. Barry
  • Patent number: 8691961
    Abstract: The present invention relates to the production and uses of flavivirus replicons and flavivirus particles and reporter virus particles. The present invention relates to the production and uses of chimeric and codon-optimized flavivirus virus replicons and flavivirus virus particles and reporter virus particles.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: April 8, 2014
    Assignee: Integral Molecular, Inc.
    Inventors: Bridget Puffer, Kimberly-Anne Mattia
  • Patent number: 8691563
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: April 8, 2014
    Assignee: Medigen, Inc.
    Inventors: Peter Pushko, Igor Lukashevich
  • Patent number: 8691505
    Abstract: The problem to be solved by the present invention is to provide a highly-efficient transformation technology, specifically, a highly-efficient promoter used for transforming algae, a vector comprising the promoter, and a method for transforming algae by using the vector. The promoter according to the present invention is characterized in comprising a polynucleotide constituting a non-coding region located upstream of a gene encoding a structural protein of a ClorDNA virus, and the like.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: April 8, 2014
    Assignee: Kochi University
    Inventors: Masao Adachi, Takuma Okami, Keizo Nagasaki, Yuji Tomaru
  • Publication number: 20140093528
    Abstract: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions.
    Type: Application
    Filed: November 25, 2013
    Publication date: April 3, 2014
    Applicant: The United States of America, as Represented by the Secretary, Dept. of Health & Human Service
    Inventor: Ira Berkower
  • Publication number: 20140093556
    Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).
    Type: Application
    Filed: January 26, 2012
    Publication date: April 3, 2014
    Applicants: SANOFI PASTEUR SA, POLYMUNE SCIENTIFIC IMMUNOBIOLOGISCHE FORSCHUNG GMBH, UNIVERSIDAD DE GRANADA, PX' THERAPEUTICS
    Inventors: Francisco Conejero-Lara, Irene Luque, Pedro Luis Mateo, Andreas Wagner, Raphaelle Claude, Marie-Gaelle Roger, Nicolas Mouz, Christophe Martin
  • Patent number: 8685409
    Abstract: There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for unpredictable epidemic influenza. The present invention selected internal genes of the consensus sequence obtained from bird, pig, and human influenza isolates in order to develop the T cell-based universal flu vaccine. The T cell-based universal flu vaccine according to the present invention is characterized by including at least one CTL epitope, by containing a plurality of internal genes and using the entire sequence of the internal gene itself. The T cell-based universal flu vaccine can achieve broad defense in infection with hetero-subtypic influenza viruses.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: April 1, 2014
    Assignee: Mogam Biotechnology Research Institute
    Inventors: Jin-Won Youn, Ji-Sun Kwon, Jung-Soon Yoon, Yeon-Jung Kim
  • Patent number: 8685720
    Abstract: The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type. A quorum sensing systems that regulates the expression of cell fate regulators is introduced into mammalian host cells, such as stem cells. The quorum sensing systems generally comprises vectors that express the components of a bacterial quorum sensing pathway, including proteins which catalyze the synthesis of an autoinducer and a gene encoding a regulatory partner of the autoinducer, and vectors in which genes encoding cell fate regulators are operably linked to a promoter induced by the autoinducer/regulatory partner complex.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: April 1, 2014
    Assignee: The Trustees of Princeton University
    Inventors: Ron Weiss, Ihor Lemischka, Priscilla E. M. Purnick, Christoph Schaniel, Miles Miller, Patrick Guye
  • Patent number: 8685405
    Abstract: Plants are produced that express an amino acid sequence that, when administered to a fish, produce an antigenic or immune response in the fish. The amino acid sequence in one embodiment is an antigen from an organism that causes pathology in fish. The plant tissue may be fed to the fish, or mixed with other materials and fed to fish, or extracted and administered to the fish.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: April 1, 2014
    Assignees: ProdiGene, Inc., Novartis AG
    Inventors: Linda Bootland, Katherine Beifuss
  • Publication number: 20140086947
    Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.
    Type: Application
    Filed: May 16, 2013
    Publication date: March 27, 2014
    Applicant: IMMUNE DESIGN CORP.
    Inventor: IMMUNE DESIGN CORP.
  • Publication number: 20140086953
    Abstract: Novel attenuating deletions of Chikungunya virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions comprising the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used for immunization of animals to provide protection from the pathogenic effects of Chikungunya virus infection.
    Type: Application
    Filed: September 26, 2013
    Publication date: March 27, 2014
    Applicant: Research Development Foundation
    Inventors: Dennis T. BROWN, Raquel HERNANDEZ
  • Patent number: 8674084
    Abstract: The inventions is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (‘CPMV-HT’) based protein expression system.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: March 18, 2014
    Assignee: Plant Bioscience Limited
    Inventors: Frank Sainsbury, George Peter Lomonossoff
  • Publication number: 20140072589
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 13, 2014
    Applicant: ZOETIS LLC
    Inventors: Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
  • Patent number: 8669419
    Abstract: The present invention relates to nucleic acid molecules useful for conferring broad and durable resistance to grapevine fanleaf virus in plants. The invention also relates to methods of enhancing resistance to plant pathogens and plants or plant components (such as grape plants) expressing such nucleic acid molecules. In addition, the invention relates to products (e.g., foodstuffs including beverages such as wine or juice) derived from grape plants transformed with such nucleic acids.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: March 11, 2014
    Assignee: Cornell University
    Inventors: Marc Fuchs, Jonathan Oliver
  • Publication number: 20140065105
    Abstract: A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
    Type: Application
    Filed: November 7, 2013
    Publication date: March 6, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: James M Wilson, Guangping Gao, Soumitra Roy
  • Publication number: 20140065599
    Abstract: Provided is a new polyomavirus, provisionally named MX polyomavirus, (MXPyV). Further provided are cDNA nucleic acid sequences, recombinant proteins, expression vectors and host cells, recombinant anti-MXPyV antibodies, vaccines, compositions, methods of detecting MXPyV, methods for assaying for anti-MXPyV compounds, and methods for treating or preventing a MXPyV infection.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 6, 2014
    Inventors: Charles CHIU, Guixia Yu, Alexander Greninger, Pavel Isa, Carlos F. Arias, Joseph De Risi, Juliet Parsonnet, Steve Miller
  • Patent number: 8663657
    Abstract: A nucleic acid construct comprising a chimeric promoter sequence and a cloning site for insertion of a coding sequence in operable linkage with the chimeric promoter, wherein the chimeric promoter sequence comprises: (a) a hCMV immediate early promoter sequence; (b) exon 1 and at least a part of exon 2 of the hCMV major immediate early gene; and (c) a heterologous intron provided in place of the intron A region of the hCMV major immediate early gene.
    Type: Grant
    Filed: October 11, 2004
    Date of Patent: March 4, 2014
    Assignee: PowderJect Vaccines, Inc.
    Inventor: James Fuller
  • Publication number: 20140056938
    Abstract: Embodiments are directed compositions related to Eilat virus and uses thereof.
    Type: Application
    Filed: June 21, 2013
    Publication date: February 27, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Scott C. Weaver, Farooq Nasar, Rodion V. Gorchakov, Hilda Guzman, Naomi Forrester, Gustavo Palacios, Ian W. Lipkin, Robert B. Tesh